United States Shingles Vaccine Market Report and Forecast 2026-2034

Study Period

2021-2034

Market (2026)

USD 1.56 Billion

Market (2034)

USD 5.03 Billion

CAGR

15.76%

Major Markets Players

GSK, Pfizer Inc, Moderna Inc., Curevo Inc., SK bioscience and Others

*Note: Partial List Randomly Ordered

United States Shingles Vaccine Market Key Takeaways

United States Shingles Vaccine Market Insights & Analysis

The United States Shingles Vaccine Market is anticipated to register a 15.76% CAGR during 2026–2034. The market size was valued at USD 1.56 billion in 2026 and is projected to reach USD 5.03 billion by 2034. This growth trajectory is supported by expanding Medicare Part D coverage for shingles immunization, increasing CDC recommendations for adults aged 50 and above, and growing awareness programs targeting immunocompromised populations. The Centers for Disease Control and Prevention reports that nearly one million Americans develop herpes zoster annually, reinforcing the clinical and economic rationale for sustained vaccine deployment.

Manufacturers across the United States Shingles Vaccine Market are directing substantial resources toward second-generation recombinant formulations and expanded label indications targeting younger immunocompromised cohorts. GSK's Shingrix has demonstrated over 90% efficacy across age groups, establishing a strong clinical benchmark that competitors including Curevo Inc. are working to match through novel adjuvant systems. Federal immunization financing through VFC-adjacent adult programs and employer-sponsored preventive care packages are further consolidating demand, particularly across community pharmacy and integrated health system channels.

United States Shingles Vaccine Market Dynamics

The United States Shingles Vaccine Market continues gaining commercial momentum as demographic aging, expanding insurance coverage, and intensifying public health communications converge to drive adult immunization uptake. Growing recognition of post-herpetic neuralgia as a debilitating and costly complication is reshaping prescriber behavior and patient willingness to pursue preventive vaccination, while accelerating payer support reinforces long-term structural demand.

Key Market Driver: Aging Population Expanding Immunization Eligibility

The United States Census Bureau projects that adults aged 65 and above will represent over 22% of the total U.S. population by 2034, creating a structurally larger and more clinically urgent target pool for herpes zoster prevention. With post-herpetic neuralgia affecting an estimated 10-18% of shingles cases and generating significant downstream healthcare costs exceeding USD 1.0 billion annually in the U.S., payers and integrated delivery networks are increasingly prioritizing shingles vaccination as a cost-effective preventive intervention. This demographic imperative is directly stimulating demand for recombinant shingles vaccine formulations across adult care settings, driving higher coverage rates among previously unvaccinated cohorts.

Major Industry Challenge: Vaccine Series Completion and Access Gaps

Despite strong clinical endorsement, the two-dose Shingrix series completion rate remains a persistent market constraint. CDC surveillance data indicate that a significant proportion of vaccine initiators do not complete the second dose within the recommended two-to-six-month window, reducing population-level protection and blunting realized market revenue per patient. Geographic and socioeconomic disparities in pharmacy access, particularly across rural Southern and Midwestern communities, further fragment demand. Addressing these completion and access barriers requires coordinated effort from pharmacy benefit managers, community health organizations, and manufacturers investing in patient reminder infrastructure and dose-bundling programs.

Emerging Trend Shaping Outlook: mRNA Vaccine Platform Expansion

Moderna Inc. and several pipeline-stage biotechnology companies are advancing mRNA-based herpes zoster vaccine candidates that leverage the thermostability, rapid manufacturing scalability, and flexible antigen design advantages demonstrated by mRNA COVID-19 platforms. Early-phase clinical data suggest competitive immunogenicity profiles against VZV glycoprotein E antigens, and mRNA-based infectious disease vaccine pipeline advancements are expected to introduce differentiated options for immunocompromised and younger adult populations by the latter forecast years. This pipeline dynamism is anticipated to intensify competitive pricing pressure on established recombinant and live-attenuated products while expanding overall vaccination awareness and uptake.

United States Shingles Vaccine Market Segment-wise Analysis

The United States Shingles Vaccine Market spans a well-defined product and technology landscape driven by differentiated clinical profiles, established prescriber preferences, and evolving pipeline entrants. Commercial performance across both primary segmentation dimensions reflects strong concentration in clinically superior offerings while emerging formats continue expanding addressable population coverage.

By Product

• Shingrix
• Zostavax
• SKYZoster

Shingrix, developed by GSK, commands an estimated 82% share of the U.S. shingles vaccine product segment following its 2017 FDA approval and subsequent CDC Advisory Committee on Immunization Practices preferential recommendation over live-attenuated alternatives. Its two-dose recombinant subunit formulation incorporating AS01B adjuvant system delivers more than 90% efficacy in adults aged 50 and above and more than 68% efficacy in adults aged 70 and above, making it the clinical standard of care. Medicare Part D formulary inclusion across major pharmacy benefit managers has further entrenched Shingrix as the default prescriber and pharmacist recommendation in both retail and clinical settings.

Zostavax, Merck's live-attenuated vaccine, has experienced significant volume erosion following the preferential Shingrix recommendation, though it retains residual utilization among specific clinical subpopulations where a single-dose administration is preferred. SKYZoster, developed by SK bioscience and targeting regulatory pathways in the U.S. market, represents an emerging competitive alternative with a distinct adjuvant-free recombinant profile. Curevo Inc.'s CRV-101 candidate, currently in late-stage clinical development, aims to address two-dose completion challenges by optimizing immunization scheduling requirements, a differentiated positioning that could capture meaningful share among pharmacy-administered adult immunization programs.

By Vaccine Type

• Recombinant Vaccine
• Live Attenuated Vaccine

Recombinant vaccines account for an estimated 86% of the U.S. shingles vaccine market by vaccine type, a dominant position reflecting the clinical, regulatory, and payer-driven displacement of earlier live-attenuated technology. The recombinant subunit approach, anchored by GSK's AS01B-adjuvanted Shingrix platform, delivers durable immune responses across older and immunocompromised adults without the safety concerns associated with replication-competent viral vectors. Growing indications for recombinant shingles vaccination in hematopoietic stem cell transplant recipients and patients on immunosuppressive therapies are expanding addressable prescription volumes beyond the standard age-defined eligible population.

Live attenuated vaccines retain a limited but stable market presence driven by single-administration convenience and lower acquisition costs in certain health system formulary contexts. However, their contraindication in immunocompromised patients and lower long-term efficacy profile relative to recombinant alternatives constrain their forward growth potential. Regulatory agencies have maintained Zostavax's approved labeling, but CDC guidance effectively channels the majority of new prescriptions toward recombinant formulations. Ongoing clinical research into next-generation adjuvanted vaccine technologies targeting older adult immunosenescence is expected to further consolidate recombinant vaccine dominance across the forecast period.

Regional Projection of United States Shingles Vaccine Market

The United States Shingles Vaccine Market exhibits meaningful regional variation shaped by population age structure, healthcare infrastructure density, insurance coverage penetration, and physician-to-patient access ratios. Commercial performance is strongest in regions with established integrated health systems and high retail pharmacy density, while emerging growth is accelerating across previously underpenetrated geographies.

• Northeast: The Northeast leads the United States Shingles Vaccine Market with approximately 31.4% revenue share, supported by dense academic medical centers, high physician immunization recommendation rates, and strong Medicare Part D penetration driving consistent two-dose series completion.
• Midwest: The Midwest maintains a stable commercial presence driven by a large and rapidly aging rural population increasingly accessing shingles vaccination through independent and chain retail pharmacies, with community health worker programs improving coverage in underserved counties.
• South: The South accounts for a significant revenue share underpinned by the region's large adult population aged 50 and above, expanding integrated delivery network immunization protocols, and manufacturer-led patient awareness campaigns targeting Hispanic and African American communities with historically lower vaccination rates.
• West: The West represents the fastest-growing regional market, supported by strong preventive healthcare culture, high health literacy among aging baby boomer cohorts concentrated in California, Oregon, and Washington, and accelerating health system-driven immunization programs embedded within annual wellness visit workflows.

United States Shingles Vaccine Market: Recent Development (2025)

• GSK expanded Shingrix manufacturing capacity to address persistent U.S. supply and demand imbalances.
• Moderna initiated Phase 2 trials for mRNA-1468, its investigational shingles vaccine candidate in adults.
• Curevo Inc. reported positive late-stage clinical data supporting CRV-101 FDA regulatory submission timelines.
• SK bioscience advanced U.S. partnership discussions to accelerate SKYZoster commercial market entry.

United States Shingles Vaccine Market Future Outlook (2034)

The United States Shingles Vaccine Market is projected to expand at a 15.76% CAGR, reaching approximately USD 5.03 billion by 2034. Market expansion will be sustained by the continuous demographic aging of the U.S. adult population, broadening clinical indications for shingles vaccination in immunocompromised patients, and increasing integration of adult immunization into value-based care contracts. Enhanced digital health infrastructure, including pharmacy-based electronic health record integration and automated patient recall systems, will materially improve two-dose series completion rates and drive per-patient revenue realization across commercial and government payer channels.

The competitive landscape will intensify as mRNA-based vaccine candidates from Moderna and other pipeline entrants approach late-stage development and potential regulatory approval, creating pricing dynamics that may expand overall market volume while compressing unit margins for established recombinant formulations. Simultaneously, the growing adoption of adult immunization scheduling platforms within integrated care delivery networks will support broader population-level coverage of the estimated 100 million eligible but unvaccinated American adults. Long-term market leadership will reward manufacturers combining superior clinical profiles with robust payer contracting, differentiated patient engagement tools, and scalable manufacturing to meet growing preventive immunization demand.

United States Shingles Vaccine Market Report Coverage

Why Choose This Report?

• Comprehensive analysis of the U.S. shingles vaccine competitive and clinical landscape.
• Accurate market sizing with reliable forecast projections through 2034.
• Detailed segmentation by product, vaccine type, and U.S. region.
• Regional insights covering Northeast, Midwest, South, and West markets.
• In-depth profiling of GSK, Moderna, Curevo Inc., and pipeline entrants.
• Analysis of recombinant and mRNA vaccine technology advancement trajectories.
• Strategic intelligence supporting investment, partnership, and commercial planning decisions.
• Data-backed research aligned with CDC immunization guidelines and payer coverage trends.